Dysregulation of voltage-gated cardiac Na channels can be arrhythmogenic. A new study shows that splice variants of fibroblast growth factor homologous factors (FHFs) can either promote or suppress arrhythmogenic late Na current, and the peptide inhibitor FixR could represent a therapeutic strategy to treat cardiac arrhythmias.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Wang, Q. et al. Cell 80, 805–811 (1995).
Hegyi, B. et al. J. Mol. Cell Cardiol. 123, 168–179 (2018).
Smallwood, P. M. et al. Proc. Natl Acad. Sci. USA 93, 9850–9857 (1996).
Lou, J. Y. et al. J. Physiol. (Lond.) 569, 179–193 (2005).
Wang, C. et al. Circ. Res. 109, 775–782 (2011).
Burel, S. et al. J. Biol. Chem. 292, 17431–17448 (2017).
Abrams, J. et al. JCI Insight 5, e141736 (2020).
Chakouri, N. et al. Nat. Cardiovasc. Res. https://doi.org/10.1038/s44161-022-00060- (2022).
Hegyi, B. et al. Basic Res. Cardiol. 116, 58 (2021).
Venkatesan, K., Liu, Y. & Goldfarb, M. J. Neurosci. 34, 16126–16139 (2014).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Hegyi, B., Bers, D.M. Fixing a current problem in the cardiac Na channel. Nat Cardiovasc Res 1, 408–409 (2022). https://doi.org/10.1038/s44161-022-00070-4
Published:
Issue Date:
DOI: https://doi.org/10.1038/s44161-022-00070-4